Vitamin B12 as a marker for disease activity in tocilizumab patients
Part of Immune system & allergy, Infections clinical trials.
This study looks at whether vitamin B12 levels in the blood can help tell if your disease is active or if you have an infection while being treated with tocilizumab. The goal is to find a simple way to monitor your condition without extra invasive tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with one of the listed conditions: rheumatoid arthritis, polymyalgia rheumatica, giant cell arteritis, systemic sclerosis, Takayasu vasculitis, Still disease, VEXAS syndrome, or an unclassified autoimmune/auto-inflammatory disease.
- You are currently receiving or will start treatment with tocilizumab (either through a vein or as a shot).
- You are willing to provide informed consent and are covered by a social protection system.
- You are not taking vitamin B12 supplements (by mouth or injection).
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at immune system blood tests in adults being treated for active tuberculosis and/or latent tuberculosis infection. The goal is to see if these “immune biomarkers” can help guide or improve tuberculosis management.
This study measures how tocilizumab (an arthritis medication) works in your body when given as an infusion. You qualify if you have rheumatoid arthritis that hasn't fully responded to other treatments but is now under control.
This trial tests whether the drug tocilizumab can help treat chronic active antibody-mediated rejection after a kidney transplant. It is for people whose kidney function is still fairly good and who have certain findings on biopsy.
This study looks at blood “biomarkers,” or measurable body signals, in people with autoimmune diseases, vasculitis, or autoinflammatory conditions. The goal is to better understand these illnesses and how they relate to disease activity.
This study follows patients with ANCA-associated vasculitis (a rare autoimmune disease affecting blood vessels) who receive rituximab, a medication that depletes certain immune cells. Researchers want to understand how the immune system recovers over time and whether this helps predict disease flares or relapses.
This study looks at different ways to measure the amount of biologic drugs in your blood. It is for people with inflammatory bowel disease who are about to start a new biologic therapy or have never taken one before.
Hear when a new Level of Serum Vitamin B12 Level (in Pmol/L) If Relapse of (AI/ID) Under Tocilizumab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.